tetano
Editor, Senior Moderator
Vaccines (Basel)
. 2021 Jun 25;9(7):698.
doi: 10.3390/vaccines9070698.
Conserved Influenza Hemagglutinin, Neuraminidase and Matrix Peptides Adjuvanted with ALFQ Induce Broadly Neutralizing Antibodies
Clara J Sei[SUP] 1 [/SUP], Mangala Rao[SUP] 2 [/SUP], Richard F Schuman[SUP] 3 [/SUP], Luke T Daum[SUP] 4 [/SUP], Gary R Matyas[SUP] 2 [/SUP], Nimisha Rikhi[SUP] 1 [/SUP], Kevin Muema[SUP] 1 [/SUP], Alexander Anderson[SUP] 2 5 [/SUP], Ousman Jobe[SUP] 2 6 [/SUP], Kellie A Kroscher[SUP] 1 [/SUP], Carl R Alving[SUP] 2 [/SUP], Gerald W Fischer[SUP] 1 [/SUP]
Affiliations
Abstract
A universal influenza candidate vaccine that targets multiple conserved influenza virus epitopes from hemagglutinin (HA), neuraminidase (NA) and matrix (M2e) proteins was combined with the potent Army liposomal adjuvant (ALFQ) to promote induction of broad immunity to seasonal and pandemic influenza strains. The unconjugated and CRM-conjugated composite peptides formulated with ALFQ were highly immunogenic and induced both humoral and cellular immune responses in mice. Broadly reactive serum antibodies were induced across various IgG isotypes. Mice immunized with the unconjugated composite peptide developed antibody responses earlier than mice immunized with conjugated peptides, and the IgG antibodies were broadly reactive and neutralizing across Groups 1 and 2 influenza viruses. Multi-epitope unconjugated influenza composite peptides formulated with ALFQ provide a novel strategy for the development of a universal influenza vaccine. These synthetic peptide vaccines avoid the pitfalls of egg-produced influenza vaccines and production can be scaled up rapidly and economically.
Keywords: ALFQ; QS21 (also known as QS-21); Th1/Th2 responses; broadly reactive antibodies; immune responses; influenza; liposomes; neutralizing antibodies; peptides; universal vaccine.
. 2021 Jun 25;9(7):698.
doi: 10.3390/vaccines9070698.
Conserved Influenza Hemagglutinin, Neuraminidase and Matrix Peptides Adjuvanted with ALFQ Induce Broadly Neutralizing Antibodies
Clara J Sei[SUP] 1 [/SUP], Mangala Rao[SUP] 2 [/SUP], Richard F Schuman[SUP] 3 [/SUP], Luke T Daum[SUP] 4 [/SUP], Gary R Matyas[SUP] 2 [/SUP], Nimisha Rikhi[SUP] 1 [/SUP], Kevin Muema[SUP] 1 [/SUP], Alexander Anderson[SUP] 2 5 [/SUP], Ousman Jobe[SUP] 2 6 [/SUP], Kellie A Kroscher[SUP] 1 [/SUP], Carl R Alving[SUP] 2 [/SUP], Gerald W Fischer[SUP] 1 [/SUP]
Affiliations
- PMID: 34202178
- DOI: 10.3390/vaccines9070698
Abstract
A universal influenza candidate vaccine that targets multiple conserved influenza virus epitopes from hemagglutinin (HA), neuraminidase (NA) and matrix (M2e) proteins was combined with the potent Army liposomal adjuvant (ALFQ) to promote induction of broad immunity to seasonal and pandemic influenza strains. The unconjugated and CRM-conjugated composite peptides formulated with ALFQ were highly immunogenic and induced both humoral and cellular immune responses in mice. Broadly reactive serum antibodies were induced across various IgG isotypes. Mice immunized with the unconjugated composite peptide developed antibody responses earlier than mice immunized with conjugated peptides, and the IgG antibodies were broadly reactive and neutralizing across Groups 1 and 2 influenza viruses. Multi-epitope unconjugated influenza composite peptides formulated with ALFQ provide a novel strategy for the development of a universal influenza vaccine. These synthetic peptide vaccines avoid the pitfalls of egg-produced influenza vaccines and production can be scaled up rapidly and economically.
Keywords: ALFQ; QS21 (also known as QS-21); Th1/Th2 responses; broadly reactive antibodies; immune responses; influenza; liposomes; neutralizing antibodies; peptides; universal vaccine.